Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References 1 GROWTH ScemblixⓇ US launch off to a strong start NBRx share (rolling 3 months) CE AZ K KL SCEMBLIX® Strong launch execution Uptake driven by patients with resistance/intolerance to other TKIs Oct 21 Sprycel Tasigna Imatinib Gleevec Bosulif Iclusig Scemblix $25m 20% NBRX share in CML (across lines) 20% 19% 49% 3L+ patient share 12% 85% FF calls F2F, supporting strong SOV 5% 1L Ph3 study enrolling ahead of plan Nov 21 Dec 21 Jan 22 Feb 22 FF Field force SOV Share of voice 14 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation